Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study,10.1007/s10072-010-0345-y,Neurological Sciences,Fredrik Piehl,C. Holmén,J. Hillert

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study   (Citations: 2)
BibTex | RIS | RefWorks Download
A post-marketing surveillance program was implemented to monitor the safety and open label efficacy of natalizumab since its launch in Sweden August 2006. Patients are registered in the Swedish multiple sclerosis (MS)-registry that has a nationwide coverage using a standardized follow-up that includes EDSS, MSSS, SDMT, MSIS-29, and recording of adverse events (AEs). As of 31 January, 2010, 1,115 patients had been included, of which 363 were treated ≥24 months. Dropout rate was 10%, mainly due to planned pregnancy. Serious AEs were rare, but included three cases of progressive multifocal leukoencephalopathy (PML), none of which had received previous immunosuppressive therapy. All analyzed clinical outcome parameters showed significant improvements compared to baseline for patients exceeding 24 months of treatment. Our results demonstrate good general tolerability and sustained efficacy of natalizumab for patients with severe MS, though the risk of PML remains a concern.
Journal: Neurological Sciences - NEUROL SCI , vol. 31, no. 2, pp. 289-293, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: